FIELD: pharmacology.
SUBSTANCE: composition of the invention contains at least 500 mg of leucine and/or at least 200 mg of one or more of its metabolites, wherein one or more leucine metabolites are selected from the group consisting of ketoisocaproic acid (KIC), alphahydroxyisocaproic acid and hydroxymethyl butyrate (HMB), and an antidiabetic agent comprising metformin. The methods of the invention comprise composition administration to a subject.
EFFECT: application of the invention can reduce the metformin dose during treatment of metabolic disorders due to the synergistic effect of the composition components.
27 cl, 3 tbl, 76 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR INCREASING ENERGY METABOLISM | 2013 |
|
RU2655794C2 |
| NORMALIZATION OF FUNCTIONS OF BIOLOGICAL PATHWAYS FOR PROTECTION AGAINST AND ELIMINATION OF DISORDERS ARISING FROM HUMAN AGING | 2016 |
|
RU2768936C2 |
| TYROSINE INHIBITORS WITH IMMUNOSUPPRESSIVE ACTIVITY IN HUMAN NEONATAL KERATINOCYTE PROGENOUS CELLS | 2020 |
|
RU2809007C2 |
| SKIN REPAIR COMPOSITIONS CONTAINING CIRCADIAN GENE ACTIVATORS AND SYNERGISTIC COMBINATION OF sirt1 GENE ACTIVATORS | 2010 |
|
RU2494756C1 |
| MODULATION OF SIRTUIN GENE IN EPIDERMAL KERATINOCYTE PRECURSORS USING DECAPEPTIDE-12 | 2018 |
|
RU2781194C2 |
| CELL PROCESS MODULATORS AND COMPOSITIONS BASED ON THEM FOR PREVENTING DEVELOPMENT OF AGE-RELATED DISEASES | 2023 |
|
RU2819911C1 |
| BICYCLIC PYRIDINES AND ANALOGUES AS SIRTUIN MODULATORS | 2010 |
|
RU2550821C2 |
| CHROMENONE ANALOGUES AS SIRTUIN MODULATORS | 2009 |
|
RU2527269C2 |
| QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS | 2009 |
|
RU2519779C2 |
| GEROPROTECTIVE FEED ADDITIVE | 2021 |
|
RU2770470C1 |
